Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advax-adjuvanted hepatitis B vaccine prevention study
ACTRN12607000598482Phase 2Completed
- Sponsor
- Vaxine
- Start
- Jul 2006
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ADVAX and hepatitis b vaccine (recombinant) in hepatitis B (HBV) (3 arms), sponsored by Vaxine. Primary endpoint: Safety assessment including adverse events and local tolerability. Started Jul 2006; status: completed.
02
Drugs
ADVAXhepatitis b vaccine (recombinant)
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ACTRN12607000598482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000598482.